Trial · NCT01004861
Adverse events4,069
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,069
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Dose Escalation Cohort 1: 200 mg QD | 0 | 3 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 2: 300 mg QD | 3 | 6 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 3: 400 mg QD | 1 | 6 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 4: 600 mg QD | 3 | 6 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 5: 900 mg/Day (500mg AM, 400mg PM) | 5 | 7 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 6: 1200 mg/Day (600mg BID) | 2 | 6 | |
| other | Fatigue | General disorders | Dose Escalation Cohort 7: 1000 mg/Day (500mg BID) | 3 | 7 | |
| other | Fatigue | General disorders | MEC Cohort 1000 mg/Day (600mg AM, 400mg PM) | 2 | 4 | |
| other | Fatigue | General disorders | PVNS Cohort 1000 mg/Day (600mg AM, 400mg PM) | 36 | 39 | |
| other | Fatigue | General disorders | GIST Cohort 1000 mg/Day (600mg AM, 400mg PM) | 7 | 11 | |
| other | Fatigue | General disorders | ATC Cohort 1000 mg/Day (600mg AM, 400mg PM) | 5 | 9 | |
| other | Fatigue | General disorders | Malignant Effusion Cohort 1000 mg/Day (600mg AM, 400mg PM) | 6 | 8 | |
| other | Fatigue | General disorders | Other Solid Tumor Type Cohort 1000 mg/Day (600mg AM, 400mg PM) | 12 | 20 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 1: 200 mg QD | 0 | 3 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 2: 300 mg QD | 0 | 6 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 3: 400 mg QD | 0 | 6 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 4: 600 mg QD | 1 | 6 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 5: 900 mg/Day (500mg AM, 400mg PM) | 2 | 7 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 6: 1200 mg/Day (600mg BID) | 2 | 6 | |
| other | Hair colour changes | Skin and subcutaneous tissue disorders | Dose Escalation Cohort 7: 1000 mg/Day (500mg BID) | 3 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01004861/events